MSD, a research-intensive biopharmaceutical company, completed the acquisition of the Dunboyne manufacturing facility of Takeda Dunboyne Biologicsed, a subsidiary of Takeda Pharmaceutical Company, a pharmaceutical company in Asia. Financial terms were not disclosed. “We are delighted to welcome the Dunboyne site to the MSD network and we look forward to working with the site leadership team and all of the existing employees to collectively realise the full potential of the facility. The Dunboyne facility will play an important role in MSD’s existing manufacturing network, both in Ireland and globally, helping to make the medicines of tomorrow that will positively impact patients globally. The addition of this state-of-the-art facility will further expand our significant manufacturing presence across Ireland and will complement the work already underway across our five sites here. Our existing Irish sites play a pivotal role in manufacturing some of our company’s most significant medicines and vaccines and I look forward to enhancing our operations even further with the addition of this new facility and its talented team to our network," Sanat Chattopadhyay, MSD Executive Vice President & President.